Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, IFA, Rapid Tests, Radio Immunoassay), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecast to 2026
[412 Pages Report] The global immunoassay market is projected to reach USD 39.0 billion by 2026 from USD 28.4 billion in 2021, at a CAGR of 6.6% during the forecast period. Growth in the immunoassay market is primarily driven by the rising incidence of chronic and infectious disease. The advancing technology of immunoassay and the increasing adoption of the immunoassay products are thrusting the growth of the market.
Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, the stringent regulatory scenario and technical hurdles of the immunoassay products may restrict market growth to a certain extent. The immunoassay market is segmented based on product, technology, specimen, application, end user and region.
To know about the assumptions considered for the study, download the pdf brochure
COVID-19 impact on the immunoassay market
The immunoassay product plays a critical role in curbing the spread of the COVID-19. In the absence of any vaccine or therapy, the diagnosis is the only effective way to control and manage the mass spread of the infections and the possible causalities. The rapid tests have emerged as an effective, fast and simple molecular tests for the surveillance of COVID-19 at large scale. The massive research, valuations and approvals of several immunoassay consumables and analyzers have alleviated the issues of the SARS-CoV2 detection. There has been a surge in the use of immunoassays such as chemiluminescence, enzyme‐linked, lateral flow‐based point‐of‐care tests, rapid tests and other technologies.
The stringent regulatory procedures for the approval of the immunoassay products and the technological hurdles of the immunoassay kits and reagents have impacted the market. The immunoassay market in several countries have witnessed massive growth amid the pandemic, owing to the mass scale diagnosis of COVID-19. Furthermore, the market is expected to elevate further with the increasing numbers of COVID-19 cases during the third wave.
Global Immunoassay Market Dynamics
DRIVER: Increasing Incidence of Chronic and Infectious Diseases, and Growing Awareness about Early Disease Diagnosis
The chronic diseases such as diabetes, cardiovascular diseases and cancer are on rise across the globe. The prevalence of infectious disease such as SARS-CoV2 (COVID-19), Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis and others, are also increasing at an alarming rate. Immunoassay diagnosis has become an instrumental part of the diagnostic regime of these diseases. The advancing technology of immunoassay are offering expedited results with higher efficacy, detection limits, sensitivity and cost-efficiency. The massive adoption of the rapid tests and point-of-care testing for diseases diagnosis and drug and alcohol abuse have thrusted the growth spurt of the global immunoassay market.
RESTRAINT: Stringent Regulatory Requirements for the Approval of Immunoassay Instruments and Consumables
The regulatory authorities of several nations have jotted stringent regulations for the approval and commercialization of immunoassay consumables and instruments. Also, the technological hurdles posed by the immunoassay kits and reagents such as cross-reactivity of the antibodies, low detection limits of the available antibodies, false negatives and others decelerates the growth of the immunoassay market.
OPPORTUNITY: Emerging Economies, Companion Diagnostics and Other Advancing Technologies.
Emerging economies such as Asia Pacific are expected to provide significant growth opportunities to players operating in the immunoassay market. The massive greying population of Asian nations such as Taiwan, Japan, China and India are increasing. The increasing significance of the companion diagnostics, technological progress of immunoassay products, condition-specific biomarkers immunoassays and other emerging technologies are propelling the growth of the immunoassay market.
CHALLENGES: Design Challenges, Lack of Skilled Professionals and Financial Hurdles.
The technicians face lots of design challenges associated with the immunoassays such as misinterpretation of results. Also, the dearth of skilled professionals in the clinical diagnostics domain have posed challenges from several decades.
Reagents & kits segment dominated the immunoassay market in 2020.
Based on product, the immunoassay market is segmented into reagents & kits and analyzers. Reagents & kits account for the largest share of the immunoassay market and is expected to grow at the highest CAGR. The large market share is attributed to their repetitive purchase and high consumption for the diagnostic purposes.
ELISA account for the largest share of the immunoassay market during the forecast period.
Based on technology, the immunoassay market is segmented into ELISA, rapid tests, western blotting, radioimmunoassays, ELISPOT and other technologies. ELISA account for the largest share of the immunoassay market. The large market share is attributed to high use of immunoassay tests to diagnose cancer, infectious diseases, and other chronic complications.
North America was the largest regional market for immunoassay market in 2020.
The immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America and the Middle East & Africa. In 2020, North America was the largest regional segment of the overall market, followed by Europe. The large share of the North American market is attributed to its well-established market which is driven by the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region.
Key Market Players
The prominent players operating in this market include Danaher (US), Thermo Fisher Scientific (US), Abbott Laboratories (US) and Roche (Switzerland).
Scope of the report
|
Report Metric |
Details |
|
Market size available for years |
2018–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
Product, Technology, Specimen, Application, End User and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America and the Middle East & Africa |
|
Companies covered |
Danaher (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche (Switzerland), Siemens Healthineer (Germany), Quidel (US), DiaSorin (Italy), bioMérieux (France), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), PerkinElmer (US) Becton, Dickinson & Company (US), Sysmex (Japan), Agilent Technologies (US), Mindray (China), QIAGEN (Netherlands), Merk KGaA (Germany), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem, Inc.(US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience, Inc (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US) and Gyros Protein Technologies (Sweden) |
This report categorizes the immunoassay market into the following segments and subsegments:
By Product
- Reagents & Kits
- ELISA Reagents & Kits
- Rapid Test Reagents & Kits
- ELISPOT Reagents & Kits
- Western Blot Reagents & Kits
- Other Reagents & Kits
- Analyzers
- By Type
- Open-Ended Systems
- Closed-Ended Systems
- By Purchase Mode
- Rental Purchase
- Outright Purchase
- By Type
By Technology
- Immunoassay/Immunochemistry
- Rapid Tests
- Enzyme-Linked Immunospot
- Western Blotting
- Radio-Immuno Assay
- Other Technologies
By Specimen
- Blood
- Saliva
- Urine
- Other Specimens
By Application
- Infectious Diseases
- Endocrinology
- Oncology
- Bone & Mineral Disorders
- Cardiology
- Blood Screening
- Autoimmune Disorders
- Allergy Diagnostics
- Toxicology
- Newborn Screening
- Other Applications
By End User
- Hospitals and Clinics
- Clinical Laboratories
- Pharmaceutical and Biotechnology Companies & CROs
- Blood Banks
- Research & Academic Laboratories
- Home Care Settings
By Region
- North America
- US
- Canada
- Europe
- Germany
- Italy
- France
- Spain
- UK
- Russia
- RoE
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Indonesia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of the Latin America
- Middle East & Africa
Recent Developments
- In February 2021, Thermo Fisher Scientific Inc. acquired the private point-of-care molecular diagnostic company Mesa Biotech
- In January 2021, Abbott received the CE Mark for its Panbio COVID-19 Ag Rapid Test Device, for the asymptomatic diagnosis of the SARS-CoV-2 virus. It also offers self-swabbing
- In December 2020, Beckman Coulter, the part of Danaher (US) company, launched the first high-quality and throughput assay called Access SARS-CoV-2 Antigen assay, for the COVID-19 antigen diagnosis, in the US
- In October 2020, Thermo Fisher Scientific launched its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test, for the diagnosis of COVID-19 antibodies
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on the immunoassay market?
The COVID-19 pandemic has a positive impact on immunoassay products. The extensive use of immunoassays for the mass scale diagnosis of the novel coronavirus has resulted in the unprecedented demand of the immunoassay reagents & kits globally. The active research on the escalating of the diagnostic capabilities, launch of several immunoassay products with advanced technologies have thrusted the market growth.
Who are the key players in the immunoassay market?
The prominent players operating in this market include Danaher (US), Thermo Fisher Scientific (US), Abbott Laboratories (US) and Roche (Switzerland).
Which product dominates in the immunoassay market?
Reagents & kits account for the largest share of the immunoassay market. The large market share is attributed to attributed to their repetitive purchase and high consumption for the diagnostic purposes.
What factors are driving the immunoassay market?
Market growth is largely driven by factors such as the rising incidence of chronic and infectious disease. The advancing technology of immunoassay and the increasing adoption of the immunoassay products are thrusting the growth of the market.
What is the market for global immunoassay?
The global immunoassay market is projected to reach USD 39.04 billion by 2026 from USD 28.40 billion in 2021, at a CAGR of 6.6% during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 44)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 IMMUNOASSAY: MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 48)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 BOTTOM-UP APPROACH
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 ECONOMIC ASSESSMENT
2.7 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. - 61)
FIGURE 11 IMMUNOASSAY MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 12 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 13 IMMUNOASSAY MARKET, BY SPECIMEN, 2021 VS. 2026 (USD BILLION)
FIGURE 14 IMMUNOASSAY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 IMMUNOASSAY MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOASSAY MARKET
4 PREMIUM INSIGHTS (Page No. - 67)
4.1 IMMUNOASSAY MARKET OVERVIEW
FIGURE 17 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS, THE KEY DRIVERS OF MARKET GROWTH
4.2 IMMUNOASSAY MARKET, BY PRODUCT (2021–2026)
FIGURE 18 REAGENTS & KITS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
4.3 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOASSAY MARKET
FIGURE 19 CHINA & INDIA TO WITNESS THE HIGHEST GROWTH RATES IN THE IMMUNOASSAY MARKET FROM 2021 TO 2026
4.4 GEOGRAPHIC MIX: IMMUNOASSAY MARKET
FIGURE 20 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
4.5 IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 72)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases, and growing awareness about early disease diagnosis
FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019, 2030, AND 2045
TABLE 1 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.1.1 Increasing use of immunoassays in oncology
TABLE 2 GLOBAL INCIDENCE OF THE TOP CANCERS IN MEN
TABLE 3 GLOBAL INCIDENCE OF THE TOP CANCERS IN WOMEN
5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics
5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications
TABLE 4 DETECTION OF DRUGS BY URINE TESTING
5.2.1.1.4 Growing geriatric population
FIGURE 24 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.2 Advancements in systems and technologies
5.2.1.3 Growth in the biotechnology and biopharmaceutical industries
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
5.2.1.4.1 Increasing drug and alcohol abuse, stringent laws mandating drug and alcohol testing
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for the approval of immunoassay instruments and consumables
5.2.2.2 Technical hurdles of immunoassay kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics in the immunoassay market
TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED
5.2.3.3 Development of condition-specific biomarkers and tests
TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS
5.2.3.4 Integration of microfluidics in immunoassays
5.2.3.5 Improving immunoassay diagnostics technologies
5.2.4 CHALLENGES
5.2.4.1 Design challenges, complexities, and the quality of antibodies
5.2.4.2 The dearth of skilled professionals
5.2.4.3 Unfavorable reimbursement scenario
5.2.4.4 Financial hurdles faced by the physicians
5.3 COVID-19 IMPACT ON THE IMMUNOASSAY MARKET
FIGURE 25 KEY PLAYERS: REVENUE IMPACT
5.4 REGULATORY OVERVIEW
5.4.1 US
TABLE 7 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
5.4.2 CANADA
FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.4.3 EUROPE
TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES
5.4.3.1 Europe: Regulatory Process for IVD Devices
5.4.4 JAPAN
5.4.4.1 Japan: Regulatory Process for IVD Devices
TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.5 CHINA
TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.6 INDIA
5.4.6.1 India: Regulatory Process for IVD Devices
5.4.7 INDONESIA
TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.4.8 RUSSIA
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.4.9 SAUDI ARABIA
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.10 MEXICO
5.4.10.1 Mexico: Regulatory Process for IVD Devices
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.11 BRAZIL
5.4.11.1 Brazil: Regulatory Process for IVD Devices
5.4.12 SOUTH KOREA
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5 TECHNOLOGY ANALYSIS
TABLE 17 CONVENTIONAL IMMUNOASSAYS METHODS AND TECHNIQUES
TABLE 18 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN THE IMMUNOASSAY MARKET
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE
TABLE 19 IMMUNOASSAY: AVERAGE SELLING PRICE IN 2021
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR IMMUNOASSAYS
TABLE 20 IMPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS OR FOR MEASURING OR CHECKING VISCOSITY, POROSITY, EXPANSION, SURFACE TENSION OR THE LIKE, OR FOR MEASURING OR CHECKING QUANTITIES OF HEAT, SOUND, OR LIGHT, N.E.S., BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 21 EXPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS OR FOR MEASURING OR CHECKING VISCOSITY, POROSITY, EXPANSION, SURFACE TENSION OR THE LIKE, OR FOR MEASURING OR CHECKING QUANTITIES OF HEAT, SOUND, OR LIGHT, N.E.S, 2016–2020 (USD MILLION)
5.8 PATENT ANALYSIS
TABLE 22 LIST OF PATENTS
5.9 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 29 DIRECT DISTRIBUTION, THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.11 ECOSYSTEM ANALYSIS OF THE IMMUNOASSAY MARKET
FIGURE 30 ECOSYSTEM ANALYSIS OF THE IMMUNOASSAY MARKET
5.11.1 ROLE IN THE ECOSYSTEM
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 23 HIGH CONSOLIDATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
5.12.1 DEGREE OF COMPETITION
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
6 IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 108)
6.1 INTRODUCTION
TABLE 24 IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 25 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN THE MARKET
TABLE 26 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
TABLE 27 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
6.2.1 ELISA REAGENTS & KITS
6.2.1.1 Elisa reagents & kits are widely used in basic research and high-throughput screening
TABLE 28 ELISA REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.2 RAPID TEST REAGENTS & KITS
6.2.2.1 Demand for rapid test reagents & kits is especially high in remote areas or cases where advanced equipment is unavailable
TABLE 29 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.3 ELISPOT REAGENTS & KITS
6.2.3.1 The rising prevalence of infectious diseases drives the market growth
TABLE 30 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.4 WESTERN BLOT REAGENTS & KITS
6.2.4.1 Western blotting is considered the gold standard for confirmation
TABLE 31 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.4.2 Other reagents & kits
TABLE 32 OTHER REAGENTS & KITS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3 ANALYZERS
TABLE 33 IMMUNOASSAY ANALYZERS AVAILABLE IN THE MARKET
TABLE 34 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
TABLE 35 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
6.3.1.1 Open-ended systems
6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users
TABLE 36 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3.1.2 Closed-ended systems
6.3.1.2.1 High precision and automation are key features of closed-ended systems
TABLE 37 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
TABLE 38 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
6.3.2.1 Rental purchase
6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental
TABLE 39 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION, 2018–2026 (USD MILLION)
6.3.2.2 Outright purchase
6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs
TABLE 40 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2018–2026 (USD MILLION)
7 IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 122)
7.1 INTRODUCTION
TABLE 41 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
7.2 ELISA
TABLE 42 KEY ELISA SYSTEMS AVAILABLE IN THE MARKET
TABLE 43 ELISA MARKET, BY REGION, 2018–2026 (USD MILLION)
7.2.1 ELISA MARKET, BY GENERATION
TABLE 44 ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
7.2.1.1 Third-generation & Above
7.2.1.1.1 Third and fourth-gen ELISA show high specificity and accuracy, leading to their wide use
TABLE 45 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2018–2026 (USD MILLION)
7.2.1.2 Second-generation & below
7.2.1.2.1 The cost-effectiveness of the first and second-gen tests supports their use, especially in developing countries
TABLE 46 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2018–2026 (USD MILLION)
7.2.2 ELISA MARKET, BY TYPE
TABLE 47 ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
7.2.2.1 CLIA
7.2.2.1.1 CLIA holds the largest share of the ELISA market, by type
TABLE 48 CLIA MARKET, BY REGION, 2018–2026 (USD MILLION)
7.2.2.2 IFA
7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens
TABLE 49 IFA MARKET, BY REGION, 2018–2026 (USD MILLION)
7.2.2.3 Colorimetric immunoassays
7.2.2.3.1 The introduction of advanced techniques will support market growth
TABLE 50 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2018–2026 (USD MILLION)
7.3 RAPID TESTS
7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN UNDERDEVELOPED/EMERGING COUNTRIES OR AREAS WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES
TABLE 51 KEY RAPID TESTS AVAILABLE IN THE MARKET
TABLE 52 RAPID TESTS MARKET, BY REGION, 2018–2026 (USD MILLION)
7.4 WESTERN BLOTTING
7.4.1 WESTERN BLOTTING IS WIDELY USED FOR TEST CONFIRMATION
TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET
TABLE 54 WESTERN BLOTTING MARKET, BY REGION, 2018–2026 (USD MILLION)
7.5 RADIOIMMUNOASSAYS
7.5.1 RIA ARE WIDELY USED FOR DIAGNOSIS AND DRUG TESTING
TABLE 55 RADIOIMMUNOASSAY MARKET, BY REGION, 2018–2026 (USD MILLION)
7.6 ELISPOT
7.6.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVES ADOPTION OF ASSAYS
TABLE 56 ELISPOT MARKET, BY REGION, 2018–2026 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 57 OTHER IMMUNOASSAY TECHNOLOGIES MARKET, BY REGION, 2018–2026 (USD MILLION)
8 IMMUNOASSAY MARKET, BY SPECIMEN (Page No. - 136)
8.1 INTRODUCTION
TABLE 58 IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
8.2 BLOOD
8.2.1 RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH, DESPITE INTRODUCTION OF TESTS USING OTHER SPECIMEN TYPES
TABLE 59 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2018–2026 (USD MILLION)
8.3 SALIVA
8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT THE MARKET GROWTH
TABLE 60 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2018–2026 (USD MILLION)
8.4 URINE
8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS
TABLE 61 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2018–2026 (USD MILLION)
8.5 OTHER SPECIMENS
TABLE 62 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2018–2026 (USD MILLION)
9 IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 142)
9.1 INTRODUCTION
TABLE 63 IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES, DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH
TABLE 64 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2026 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING DIABETES INCIDENCE DRIVES DEMAND FOR IMMUNOASSAYS
TABLE 65 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2018–2026 (USD MILLION)
9.4 CARDIOLOGY
9.4.1 INCREASING PREVALENCE OF CVD DRIVES MARKET GROWTH
TABLE 66 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY
TABLE 67 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2018–2026 (USD MILLION)
9.5 AUTOIMMUNE DISORDERS
9.5.1 HIGH PREVALENCE OF AUTOIMMUNE DISEASES AND RISING ECONOMIC BURDEN OF TREATMENT
TABLE 68 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
TABLE 69 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2018–2026 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 PREVALENCE OF ALLERGIES EXPECTED TO REGISTER DRASTIC INCREASE
TABLE 70 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2018–2026 (USD MILLION)
9.7 ONCOLOGY
9.7.1 RISING BURDEN OF CANCER AND GROWING GERIATRIC POPULATION SUPPORT MARKET GROWTH
TABLE 71 US CANCER INCIDENCE, BY TYPE, 2018 VS 2025
TABLE 72 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2018–2026 (USD MILLION)
9.8 BONE & MINERAL DISORDERS
9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 73 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS
TABLE 74 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2018–2026 (USD MILLION)
9.9 TOXICOLOGY
9.9.1 RISING DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY
TABLE 75 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING
TABLE 76 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS
TABLE 77 IMMUNOASSAY MARKET FOR TOXICOLOGY, BY REGION, 2018–2026 (USD MILLION)
9.10 BLOOD SCREENING
9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS
TABLE 78 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2018–2026 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 IMMUNOASSAYS ARE USED AS A FIRST-TIER NEWBORN SCREENING PROTOCOL
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING
TABLE 80 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2018–2026 (USD MILLION)
9.12 OTHER APPLICATIONS
TABLE 81 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2026 (USD MILLION)
10 IMMUNOASSAY MARKET, BY END USER (Page No. - 157)
10.1 INTRODUCTION
TABLE 82 IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH
TABLE 83 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018–2026 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS
TABLE 84 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018–2026 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVE DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY
TABLE 85 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2018–2026 (USD MILLION)
10.5 HOME CARE SETTINGS
10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH
TABLE 86 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2018–2026 (USD MILLION)
10.6 BLOOD BANKS
10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING
TABLE 87 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2018–2026 (USD MILLION)
10.7 RESEARCH & ACADEMIC LABORATORIES
10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH
TABLE 88 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018–2026 (USD MILLION
11 IMMUNOASSAY MARKET, BY REGION (Page No. - 166)
11.1 INTRODUCTION
TABLE 89 IMMUNOASSAY MARKET, BY REGION, 2018–2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 90 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 91 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 92 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 93 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 94 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 96 NORTH AMERICA: ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
TABLE 97 NORTH AMERICA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 98 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.2.1 US
11.2.1.1 The US dominates the North American market
TABLE 101 US: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 102 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 103 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 104 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 105 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 106 US: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 107 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 108 US: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 109 US: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.2.2 CANADA
TABLE 110 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 111 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 112 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 113 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 114 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 115 CANADA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 116 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 117 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 118 CANADA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3 EUROPE
FIGURE 32 EUROPE: IMMUNOASSAY MARKET SNAPSHOT
TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 121 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 122 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 123 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 124 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 125 EUROPE: ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
TABLE 126 EUROPE: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 127 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 128 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 129 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany holds the largest share of the EU immunoassay market
TABLE 130 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 131 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 132 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 133 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 134 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 135 GERMANY: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 137 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 138 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.2 ITALY
11.3.2.1 Growing geriatric population and increasing support for research drives market growth
TABLE 139 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 140 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 141 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 142 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 143 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 144 ITALY: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 145 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 146 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 147 ITALY: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising use of POC testing and favorable reimbursement policy contribute to market growth in France
TABLE 148 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 149 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 150 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 151 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 152 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 153 FRANCE: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 154 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 155 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.4 SPAIN
11.3.4.1 Growth of the geriatric population and rising demand for testing support the market in Spain
TABLE 157 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 158 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 159 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 160 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 161 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 162 SPAIN: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 163 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 164 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 165 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.5 UK
11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive the market in the UK
TABLE 166 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 167 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 168 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 169 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 170 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 171 UK: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 172 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 173 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 174 UK: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.6 RUSSIA
11.3.6.1 Lack of reimbursement and delays in approval may hinder the market growth
TABLE 175 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 176 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 177 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 178 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 179 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 180 RUSSIA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 181 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 182 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 183 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 184 ROE: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 185 ROE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 186 ROE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 187 ROE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 188 ROE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 189 ROE: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 190 ROE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 191 ROE: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 192 ROE: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 195 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 196 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 197 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 199 ASIA PACIFIC: ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
TABLE 200 ASIA PACIFIC: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 201 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 202 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 203 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Japan dominates the APAC market
TABLE 204 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 205 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 206 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 207 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 208 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 209 JAPAN: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 210 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 211 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 212 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Opportunities for growth in the Chinese market tempered by long product approval and registration processes
TABLE 213 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 214 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 215 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 216 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 217 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 218 CHINA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 219 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 220 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 221 CHINA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing medical tourism and healthcare infrastructure will drive the use of immunoassays in India
TABLE 222 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 223 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 224 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 225 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 226 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 227 INDIA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 228 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 229 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 230 INDIA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Growing disease incidence and technological development drive market growth
TABLE 231 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 232 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 233 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 234 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 235 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 236 AUSTRALIA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 237 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 238 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 239 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Rising healthcare spending and investments in research are driving market growth
TABLE 240 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 241 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 242 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 243 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 244 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 245 SOUTH KOREA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 246 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 247 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 248 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.6 INDONESIA
11.4.6.1 Indonesia has become a promising market and growth hotspot for foreign investors
TABLE 249 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 250 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 251 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 252 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 253 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 254 INDONESIA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 255 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 256 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 257 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 258 ROAPAC: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 259 ROAPAC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 260 ROAPAC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 261 ROAPAC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 262 ROAPAC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 263 ROAPAC: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 264 ROAPAC: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 265 ROAPAC: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 266 ROAPAC: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.5 LATIN AMERICA
TABLE 267 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 268 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 269 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 270 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 271 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 272 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 273 LATIN AMERICA: ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
TABLE 274 LATIN AMERICA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 275 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 277 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Brazil held the largest share of the LATAM market in 2020
TABLE 278 BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS
TABLE 279 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 280 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 281 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 282 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 283 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 284 BRAZIL: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 285 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 286 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 287 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Growing lab consolidation is expected to reduce the number of labs in Mexico
TABLE 288 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 289 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 290 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 291 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 292 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 293 MEXICO: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 294 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 295 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 296 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 297 ROLATAM: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 298 ROLATAM: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 299 ROLATAM: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 300 ROLATAM: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 301 ROLATAM: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 302 ROLATAM: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 303 ROLATAM: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 304 ROLATAM: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 305 ROLATAM: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MEA ACCOUNTS FOR A SMALL SHARE OF THE GLOBAL MARKET
TABLE 306 MEA: IMMUNOASSAY MARKET, BY PRODUCT, 2018–2026 (USD MILLION)
TABLE 307 MEA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 308 MEA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 309 MEA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018–2026 (USD MILLION)
TABLE 310 MEA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION)
TABLE 311 MEA: ELISA MARKET, BY GENERATION, 2018–2026 (USD MILLION)
TABLE 312 MEA: ELISA MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 313 MEA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018–2026 (USD MILLION)
TABLE 314 MEA: IMMUNOASSAY MARKET, BY APPLICATION, 2018–2026 (USD MILLION)
TABLE 315 MEA: IMMUNOASSAY MARKET, BY END USER, 2018–2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 294)
12.1 OVERVIEW
FIGURE 34 KEY DEVELOPMENTS IN THE IMMUNOASSAY MARKET, JANUARY 2017–APRIL 2021
FIGURE 35 MARKET EVALUATION MATRIX, 2017-2020
12.2 MARKET SHARE ANALYSIS
FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2020
12.3 COMPANY EVALUATION QUADRANT
12.3.1 STARS
12.3.2 EMERGING LEADERS
12.3.3 PERVASIVE PLAYERS
12.3.4 PARTICIPANTS
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
12.4 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
12.4.1 PROGRESSIVE COMPANIES
12.4.2 STARTING BLOCKS
12.4.3 RESPONSIVE COMPANIES
12.4.4 DYNAMIC COMPANIES
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS/SMES 300
12.5 COMPETITIVE SCENARIO
12.5.1 PRODUCT LAUNCHES & APPROVALS
TABLE 316 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2017–2021
12.5.2 DEALS
TABLE 317 IMMUNOASSAY MARKET: DEALS, 2017–2021
12.5.3 OTHER DEVELOPMENTS
TABLE 318 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2017–2021
12.6 COMPANY PRODUCT FOOTPRINT
FIGURE 39 PRODUCT PORTFOLIO ANALYSIS: IMMUNOASSAY MARKET
12.7 COMPANY GEOGRAPHIC FOOTPRINT
FIGURE 40 GEOGRAPHIC REVENUE MIX: IMMUNOASSAY MARKET (2020)
13 COMPANY PROFILES (Page No. - 306)
13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1.1 DANAHER CORPORATION
TABLE 319 DANAHER: BUSINESS OVERVIEW
FIGURE 41 DANAHER: COMPANY SNAPSHOT (2020)
13.1.2 THERMO FISHER SCIENTIFIC
TABLE 320 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
13.1.3 ABBOTT LABORATORIES
TABLE 321 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.4 ROCHE DIAGNOSTICS
TABLE 322 F. HOFFMAN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2020)
13.1.5 SIEMENS HEALTHINEERS
TABLE 323 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
13.1.6 QUIDEL CORPORATION
TABLE 324 QUIDEL: BUSINESS OVERVIEW
FIGURE 46 QUIDEL: COMPANY SNAPSHOT (2020)
13.1.7 DIASORIN
TABLE 325 DIASORIN: BUSINESS OVERVIEW
FIGURE 47 DIASORIN: COMPANY SNAPSHOT (2019)
13.1.8 BIOMÉRIEUX
TABLE 326 BIOMÉRIEUX: BUSINESS OVERVIEW
FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2019)
13.1.9 BIO-RAD LABORATORIES
TABLE 327 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 49 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.10 ORTHO CLINICAL DIAGNOSTICS
TABLE 328 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
13.1.11 PERKINELMER
TABLE 329 PERKINELMER: BUSINESS OVERVIEW
FIGURE 50 PERKINELMER: COMPANY SNAPSHOT (2020)
13.1.12 BECTON, DICKINSON & COMPANY
TABLE 330 BD: BUSINESS OVERVIEW
FIGURE 51 BD: COMPANY SNAPSHOT (2020)
13.1.13 SYSMEX CORPORATION
TABLE 331 SYSMEX: BUSINESS OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019)
13.1.14 AGILENT TECHNOLOGIES
TABLE 332 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2020)
13.1.15 MINDRAY
TABLE 333 MINDRAY: BUSINESS OVERVIEW
13.1.16 QIAGEN
TABLE 334 QIAGEN: BUSINESS OVERVIEW
FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2020)
13.2 OTHER COMPANIES/START-UPS
13.2.1 MERCK KGAA
13.2.2 BIO-TECHNE
13.2.3 CELLABS
13.2.4 ABNOVA CORPORATION
13.2.5 J. MITRA & CO.
13.2.6 TOSOH CORPORATION (TOSOH BIOSCIENCES)
13.2.7 CELL SCIENCES
13.2.8 ENZO BIOCHEM
13.2.9 CREATIVE DIAGNOSTICS
13.2.10 BOSTER BIOLOGICAL TECHNOLOGY
13.2.11 ELABSCIENCE
13.2.12 WAK-CHEMIE MEDICAL
13.2.13 SERA CARE
13.2.14 EPITOPE DIAGNOSTICS
13.2.15 KAMIYA BIOMEDICAL COMPANY
13.2.16 GYROS PROTEIN TECHNOLOGIES
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 401)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the immunoassay market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunoassay market. The secondary sources used for this study include National Center for Biotechnology Information (NCBI), Springer Nature, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Nature Journals, Springer Journals, US Food and Drug Administration (US FDA), Annual Reports, SEC Filings, Investor Presentations, and Press Releases of Key Players., Association Of Diagnostics Manufacturers Of India, BIVDA - The British In Vitro Diagnostic Association, EDMA - European Diagnostic Manufacturers Association, White Papers, Journals/Magazines, and News Articles, SEC Filings, Annual Reports, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the immunoassay market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the immunoassay business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global immunoassay market based on the product, technology, specimen, application, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall immunoassay market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the sterilization container systems market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Get in-depth analysis of the COVID-19 impact on the Immunoassay Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Immunoassay Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Immunoassay Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Immunoassay Market